Preferred Label : Uprevstobart;
NCIt definition : A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster
of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating
and antineoplastic activities. Upon administration, uprevstobart targets and binds
to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents CD73-mediated
conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated
suppression of lymphocyte activity and trafficking. This attenuates the adenosine-induced
immunosuppression in tumor microenvironment (TME), increases the activity of cytotoxic
T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived
suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory
effect on the immune system and enhancing the CTL-mediated immune response against
cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging
to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types
and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable
nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression
within the TME.;
UNII : BH6FYV3BSC;
CAS number : 2762201-85-2;
Molecule name : INCA-00186; INCA 00186;
NCI Metathesaurus CUI : CL1664819;
Origin ID : C182010;
UMLS CUI : C5557418;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
